In vivo evaluation of [123I]-8-[4-[2-(5-iodothienyl)]-4-oxobutyl]-3-methyl-1-phenyl-1,3 ,8-tri azaspiro[4.5]decan-4-one as a potential dopamine D2 receptor radioligand for SPECT.
Waterhouse
R N
RN
Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA.
Gotsick
J T
JT
Kabalka
G W
GW
Goodman
M M
MM
O'Brien
J C
JC
D000818:Animals; D001921:Brain / Q000378:metabolism; D007093:Imidazoles / Q000378:metabolism* / Q000493:pharmacokinetics; D007457:Iodine Radioisotopes; D008297:Male; D011869:Radioligand Assay; D019275:Radiopharmaceuticals / Q000378:metabolism* / Q000493:pharmacokinetics; D051381:Rats; D017208:Rats, Wistar; D017448:Receptors, Dopamine D2 / Q000378:metabolism* / Q000502:physiology; D013141:Spiro Compounds / Q000378:metabolism* / Q000493:pharmacokinetics; D015899:Tomography, Emission-Computed, Single-Photon
C111014:8-(4-(2-(5-iodothienyl))-4-oxobutyl)-3-methyl-1-phenyl-1,3,8-triazaspiro(4.5)decan-4-one; D007093:Imidazoles; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D017448:Receptors, Dopamine D2; D013141:Spiro Compounds